Registration Dossier
Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-609-3 | CAS number: 65-45-2
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 3 (not reliable)
- Rationale for reliability incl. deficiencies:
- other: Significant methodological deficiencies.
Data source
Reference
- Reference Type:
- publication
- Title:
- 3-Hydroxylation of salicylamide in mice
- Author:
- Howell SR, Kotkoskie LA, Dills RL, Klaassen CD
- Year:
- 1 988
- Bibliographic source:
- J. Pharm. Sci. 1988, 77(4), 309-313
Materials and methods
- Objective of study:
- metabolism
Test guideline
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- The concentrations of salicylamide and its metabolites in blood and urine were determined at various time points after intraperitoneal injection of salicyclamide into mice.
- GLP compliance:
- no
Test material
- Reference substance name:
- Salicylamide
- EC Number:
- 200-609-3
- EC Name:
- Salicylamide
- Cas Number:
- 65-45-2
- Molecular formula:
- C7H7NO2
- IUPAC Name:
- salicylamide
- Details on test material:
- - Name of test material (as cited in study report): salicylamide
Constituent 1
- Radiolabelling:
- no
Test animals
- Species:
- mouse
- Strain:
- CF-1
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Sasco, Omaha, NE, USA
- Weight at study initiation: 25-30 g
- Diet (e.g. ad libitum): ad libitum Purina Laboratory Rodent Chow
- Water (e.g. ad libitum): ad libitum
ENVIRONMENTAL CONDITIONS
- Temperature (°C): controlled
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- intraperitoneal
- Vehicle:
- physiological saline
- Details on exposure:
- TEST MATERIAL
- concentration (if solution): 20 mL/kg bw - Duration and frequency of treatment / exposure:
- Single exposure
Doses / concentrations
- Remarks:
- Doses / Concentrations:
274.3 mg/kg bw and 548.5 mg/kg bw (2 and 4 mmol/kg bw)
- No. of animals per sex per dose / concentration:
- 274.3 mg/kg bw: 4 mice
548.5 mg/kg bw: 8 mice - Control animals:
- yes
- Positive control reference chemical:
- no
- Details on dosing and sampling:
- PHARMACOKINETIC STUDY
- Tissues and body fluids sampled: urine, blood
METABOLITE CHARACTERISATION STUDIES
- Tissues and body fluids sampled: urine
- From how many animals: (samples pooled or not): 4-8, pooled samples
- Method type(s) for identification: HPLC-UV (240 nm)
TREATMENT FOR CLEAVAGE OF CONJUGATES (if applicable): beta-glucuronidase: sulfatase
Results and discussion
Metabolite characterisation studies
- Metabolites identified:
- yes
- Details on metabolites:
- IDENTIFIED METABOLITES:
2.3-dihydroxybenzamide (2,3-DBA), 2.5-dihydroxybenzamide (gentisamide), and their sulfates and glucuronides
QUANTIFICATION IN BLOOD:
After intraperitoneal administration of salicylamide, gentisamide glucuronide and salicylamide glucuronide were the major metabolites present in blood, followed by 2,3-DBA glucuronide and salicylamide sulfate. Gentisamide and its sulfate were detected in trace amounts only whereas neither 2.3-DBA nor its sulfate were detected.
QUANTIFICATION IN URINE:
The relative amount of each metabolite in urine generally reflected its maximum concentration in blood. Gentisamide glucuronide was the most abundant metabolite, followed by 2,3-DBA glucuronide and salicylamide sulfate. Unconjugated gentisamide and 2,3-DBA only accounted for a minor proportion; salicylamide was not detected.
Applicant's summary and conclusion
- Conclusions:
- Interpretation of results (migrated information): no bioaccumulation potential based on study results
After i.p. administration of salicylamide into mice, 2,3-dihydroxybenzamide, 2,5-dihydroxybenzamide (gentisamide), and its sulfates and glucuronides could be identified as metabolites of salicylamide in both blood and urine. - Executive summary:
Metabolism of salicylamide in mice was assessed after intraperitoneal administration of 274.3 and 548.5 mg/kg bw. The concentrations of salicylamide and its metabolites in blood and urine were determined at various time points using HPLC-UV. Glucuronides and sulfates were detected using glucuronidase/sulfatase treatment of samples before injection.
2.3-Dihydroxybenzamide (2,3-DBA), 2.5-dihydroxybenzamide (gentisamide), and their sulfates and glucuronides were identified besides the sulfates and glucuronides of salicylamide as major metabolites of salicylamide in blood and urine.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
